The PD-1/PD-L1 pathway represents an adaptive immune resistance mechanism exerted by tumor cells for immune escape and has a high impact on the efficacy of cancer therapy.67 LYTACs created with Ctx and atezolizumab mediated selective loss of EGFR and PD-L1 by more than 70% within 48 h of treatment in several cell lines. Here, EGFR is linked to cancer.